Skip to main content
Clinical Trials/NCT00854932
NCT00854932
Unknown
Not Applicable

Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study

Luzerner Kantonsspital1 site in 1 country1,600 target enrollmentJune 2009
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Luzerner Kantonsspital
Enrollment
1600
Locations
1
Primary Endpoint
The absolute reduction of the duration of antibiotic therapy with unchanged outcome
Last Updated
10 years ago

Overview

Brief Summary

In neonates, clinical signs and symptoms associated with early-onset sepsis are non-specific and currently available tests have poor positive and negative predictive values. The investigators hypothesize that procalcitonin (PCT) has a reliable negative predictive values to allow a reduction in duration of empiric antibiotic therapy in suspected neonatal early-onset sepsis with unchanged outcome. This study is designed as a multi-center, prospective, randomized intervention trial. The duration of antibiotic therapy in the standard group is based on the attending physician's assessment of the probability of infection during hospitalisation. In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.

Detailed Description

Detailed description according our pilot study (see reference). This trial is designed to exclude a difference in rate of re-infection or death greater than 2%. Assuming a 2% reinfection/death rate in each group, 770 patients are required for a power of 80% at alpha=0.05. To allow for some unevaluable cases 800 per group will be included. Based on the data of the pilot study (see reference), with a number of 770 per group a difference between mean antibiotic therapy durations of 10 hours can be detected at two-sided alpha of 0.05 with a power of 95%.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
August 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stocker Martin

MD

Luzerner Kantonsspital

Eligibility Criteria

Inclusion Criteria

  • Term and near term infants with a gestational age \> 34 weeks
  • Suspected sepsis in the first 3 days of life requiring empiric antibiotic therapy
  • Parental consent

Exclusion Criteria

  • Surgery in the first week of life
  • Severe congenital malformations

Outcomes

Primary Outcomes

The absolute reduction of the duration of antibiotic therapy with unchanged outcome

Time Frame: 1 month

Unchanged outcome = proportion of infants with a recurrence of infection requiering additional courses of antibiotic therapy within 72 hours after ending antibiotic therapy and/or death in the first month of life

Secondary Outcomes

  • Duration of hospitalisation(1 month)

Study Sites (1)

Loading locations...

Similar Trials